WO2023214314 - VODOBATINIB FOR REDUCING PROGRESSION OF PARKINSON'S DISEASE
National phase entry:
Publication Number
WO/2023/214314
Publication Date
09.11.2023
International Application No.
PCT/IB2023/054572
International Filing Date
02.05.2023
Title **
[English]
VODOBATINIB FOR REDUCING PROGRESSION OF PARKINSON'S DISEASE
[French]
VODOBATINIB POUR FREINER LA PROGRESSION DE LA MALADIE DE PARKINSON
Applicants **
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
Inventors
YAO, Siu-Long
RAMANATHAN, Vikram Krishna
DAMLE, Nitin Krishnaji
GOLDFINE, Andrew
FAULKNER, Robert D.
MANDHANE, Sanjay Nandlalji
TALLURI, Ravi Sankar Prasad
Priority Data
202221025575
02.05.2022
IN
202221062155
01.11.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4825 | |
| EPO | Filing, Examination, Granting | 57117 | |
| Japan | Filing, Examination, Granting | 3884 | |
| South Korea | Filing, Examination, Granting | 5626 | |
| USA | Filing, Examination, Granting | 23640 |
Total:
95,092
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the c-Abl inhibitor vodobatinib, or a pharmaceutically acceptable salt thereof, for use in treating, delaying, inhibiting, or suppressing the progression of neurodegenerative diseases, preferably early stage Parkinson's disease, in a subject.[French]
La présente invention concerne l'inhibiteur de c-Abl vodobatinib, ou un sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé pour traiter, retarder, inhiber ou empêcher la progression de maladies neurodégénératives, de préférence de la maladie de Parkinson au stade précoce, chez un sujet.